FDA Approves Monthly Subcutaneous Olanzapine for Schizophrenia Treatment

The FDA has approved Weltruza, a new once-monthly subcutaneous olanzapine formulation by Teva Pharmaceuticals, for adult schizophrenia treatment. This marks the first and only monthly subcutaneous olanzapine requiring no loading doses, oral supplementation, or post-injection monitoring, potentially simplifying long-term management for patients. The approval is based on the phase 3 SOLARIS trial.